Accelerate Diagnostics, Inc.
AXDXUnlisted companyAccelerate Diagnostics, Inc. in brief
Accelerate Diagnostics, Inc. is an unlisted company in the Diagnostics and Research industry, based in Tucson, Arizona, USA. It was founded in 1987. In the year to December 2024 it had sales of $12 M and a net loss of $50 M. It employs about 275 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics is an Vitro Diagnostics company. The headquarters is in USA.
Accelerate Diagnostics, Inc. timeline
- 1987
- 🏁· approximateFounded
- 1995
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- 🔔· approximateInitial public offering on Nasdaq as AXDX
- ✎Renamed Accelerate Diagnostics, IncFormerly Accelr8 Technology Corp.
- 2022
- 💰Record revenue of $13 millionFY2022, the highest of the 7 years on record.
Events of Accelerate Diagnostics, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Accelerate Diagnostics, Inc.
- Acquisitions and changes
- Delisted: the exchange removed its shares from listing (Form 25-NSE) on 21 July 2025.
Market cap history
World rank over time
Rank in USA: #1,984 (Jan 2020) · #2,865 (Jan 2021) · #3,408 (Jan 2022) · #4,692 (Dec 2022) · #4,235 (Jul 2023) · #3,996 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -427.7%
- Operating margin
- -301.8%
- Return on equity
- —
- Liabilities / assets
- 296.2%
- Net debt
- $-40M
- Revenue growth
- -3.0%
- R&D / revenue
- 142.6%
- Revenue per employee
- $43 K
- Profit per employee
- $-182 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $12M | -3.0% | $-35M | $-50M | -427.7% |
| Dec 2023 | $12M | -5.4% | $-54M | $-62M | -510.9% |
| Dec 2022 | $13M | +8.2% | $-63M | $-62M | -490.1% |
| Dec 2021 | $12M | +5.6% | $-72M | $-78M | -659.6% |
| Dec 2020 | $11M | +20.0% | $-64M | $-78M | -700.8% |
| Dec 2019 | $9M | +64.0% | $-73M | $-84M | -906.5% |
| Dec 2018 | $6M | +35.6% | $-80M | $-88M | -1557.8% |
| Dec 2017 | $4M | — | $-64M | $-64M | -1531.8% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $-24M | $1M | $-25M | $-2.15 | — |
| Dec 2023 | $-40M | $1M | $-41M | $-4.94 | — |
| Dec 2022 | $-49M | $1M | $-49M | $-7.61 | — |
| Dec 2021 | $-47M | $1M | $-48M | $-12.59 | — |
| Dec 2020 | $-50M | $1M | $-52M | $-1.40 | — |
| Dec 2019 | $-65M | $0M | $-65M | $-1.55 | — |
| Dec 2018 | $-68M | $1M | $-69M | $-1.62 | — |
| Dec 2017 | $-56M | $3M | $-59M | $-1.18 | — |
Quarterly results
Latest quarter to Dec 2024: revenue $3M (-7.3% on a year earlier), net income $-10M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Dec 2024.
SEC filings
- Aug 18, 20258-KCurrent reportMaterial agreement · Bankruptcy · Acquisition or disposal completed
- Jun 4, 20258-KCurrent reportMaterial agreement
- May 28, 20258-KCurrent reportDirectors or officers changed
- May 12, 20258-KCurrent reportListing notice
- May 8, 20258-KCurrent reportMaterial agreement · Bankruptcy · New financial obligation · Regulation FD disclosure · Other events
- Apr 30, 202510-K/AAnnual report (amended) · period to Dec 2024
- Apr 25, 20258-KCurrent reportDirectors or officers changed
- Apr 15, 20258-KCurrent reportDirectors or officers changed
- Mar 21, 20258-KCurrent reportOther events
- Mar 21, 20258-KCurrent reportResults of operations
- Mar 21, 202510-KAnnual report · period to Dec 2024
- Jan 30, 20258-KCurrent reportListing notice
Official filings of Accelerate Diagnostics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $12 M
- Operating income
- $-35 M
- Net income
- $-50 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $29 M
- Total liabilities
- $85 M
- Total equity
- $-56 M
As of December-2024
Insider trading at Accelerate Diagnostics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Larry Michael MertzChief Technology Officer | Option exercise | +4,298 | — | — | 86,326 | Form 4 |
| filed | Jack PhillipsChief Executive Officer, Director | Option exercise | +53,283 | — | — | 216,717 | Form 4 |
| filed | Larry Michael MertzChief Technology Officer | Sell | -1,523 | $0.650 | $990 | 84,803 | Form 4 |
| filed | Jack PhillipsChief Executive Officer, Director | Sell | -25,343 | $0.650 | $16 K | 191,374 | Form 4 |
| filed | David PatienceChief Financial Officer | Option exercise | +20,000 | — | — | 71,384 | Form 4 |
| filed | David PatienceChief Financial Officer | Sell | -6,816 | $0.710 | $5 K | 64,568 | Form 4 |
| filed | David PatienceChief Financial Officer | Option exercise | +1,500 | — | — | 51,919 | Form 4 |
| filed | David PatienceChief Financial Officer | Sell | -535 | $1.090 | $583 | 51,384 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Accelerate Diagnostics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split
Bankruptcy filing: (8-K); (8-K)
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2019 | Q4 2019 | $0M |
| Q3 2019 | Q3 2019 | $0M |
| Q2 2019 | Q2 2019 | $0M |
| Q1 2019 | Q1 2019 | $0M |
| Q4 2018 | Q4 2018 | $0M |
| Q3 2018 | Q3 2018 | $0M |
| Q2 2018 | Q2 2018 | $0M |
| Q1 2018 | Q1 2018 | $45.1M |
| Q4 2017 | Q4 2018 | $0M |
| Q3 2017 | Q3 2018 | $0M |
| Q2 2017 | Q2 2018 | $0M |
| Q1 2017 | Q1 2018 | $0M |
Fails to deliver
- : 1.2 M shares at $0.03
- : 19,615 shares at $0.13
- : 22,147 shares at $0.15
- : 115 shares at $0.49
- : 189 shares at $0.52
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Accelerate Diagnostics, Inc. scorecard#
Passes 2 of the 13 checks that could be worked out: strongest in profitability (1 of 4), weakest in growth (1 of 6). Fiscal year 2024.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 6
- ✗Revenue grew in the newest year-3.0%Revenue down 3.0% in fiscal 2024.
- ✗Revenue up more than 5% a year over three years-0.2%-0.2% a year over the three years to fiscal 2024.
- ✗Faster growth over three years than its peers' median-0.2%-0.2% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-2.15 vs -4.94Diluted EPS -2.15 in fiscal 2024 against -4.94 the year before (report's currency).
- ✓Net income higher than five years earlier-$50 M-$50 M in fiscal 2024 against -$84 M in 2019.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2024.
Profitability1 of 4
- ✗Profitable in the newest year-$50 MNet income -$50 M in fiscal 2024.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
- ✗Operating margin above its peers' median-301.8%-301.8% against Diagnostics and Research's median of -2.4% (66 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-301.8%-301.8% in fiscal 2024 against -607.5% in 2021.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.7×Current ratio 0.71 at the end of fiscal 2024.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year86.8%Diluted shares up 86.8% in fiscal 2024.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from Accelerate Diagnostics, Inc.'s statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | -301.8% | -2.4% | |
| Net margin | -427.7% | -3.6% | |
| Revenue growth, 3 years a year | -0.2% | 3.6% | |
| Revenue growth | -3.0% | 6.6% | |
| Free cash flow margin | -211.1% | 4.7% |
4of 8on the Piotroski tests of financial strength
- Revenue fell 3.0% against the year before.
- Net loss of $50 million, the 14th loss-making year in a row.
- Free cash flow was negative: -$25 million.
- The share count rose 86.8% in the year.
Accelerate Diagnostics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 12−3.0%100% | 12−5.4%100% | 13+8.2%100% | 12+5.5%100% | 11+20.1%100% | 9.3+64.0%100% | 5.7+35.7%100% | 4.2+1598%100% | 0.2+67.3%100% | 0.1—100% | |
| Cost of revenue | 9.0−5.4%76.9% | 9.5+0.6%78.9% | 9.4−22.3%74.1% | 12+81.4%103% | 6.7+36.9%60.1% | 4.9+53.7%52.7% | 3.2+218%56.2% | 1.0—24.0% | 0—0.0% | 0—0.0% | |
| Gross profit | 2.7+6.0%23.1% | 2.6−22.8%21.1% | 3.3—25.9% | −0.4−109%−3.2% | 4.5+1.3%39.9% | 4.4+77.2%47.3% | 2.5−21.8%43.8% | 3.2+1191%76.0% | 0.2+67.3%100% | 0.1—100% | |
| Research and development | 17−34.2%143% | 25−5.8%210% | 27+22.7%211% | 22+3.2%186% | 21−16.1%190% | 25−8.3%273% | 28+23.9%487% | 22−24.6%534% | 30r28+8.9%12018% | 27r26—18464% | |
| Selling, general and administrative | 21−31.7%182% | 31−20.3%259% | 39−20.4%307% | 49+5.0%418% | 47−9.6%420% | 52−6.0%558% | 55+22.5%974% | 45+21.2%1079% | 37—15115% | — | |
| General and administrative | — | — | — | — | — | — | — | 45+21.2%1079% | 37r36+100%15115% | 19r18—12622% | |
| Total costs and expenses | 38−32.8%325% | 57−14.4%469% | 66−7.1%518% | 71+4.4%604% | 68−11.7%610% | 77−6.8%831% | 83+23.0%1461% | 67+0.9%1613% | 67+46.1%27133% | 46—31086% | |
| Operating income | −35—−302% | −54—−448% | −63—−493% | −72—−607% | −64—−571% | −73—−783% | −80—−1417% | −64—−1537% | −67—−27033% | −46—−30986% | |
| Interest and finance income | 0.7−37.4%6.0% | 1.1+104%9.3% | 0.6+526%4.3% | 0.1−89.7%0.7% | 0.9−69.6%7.7% | 2.8−1.3%30.2% | 2.8+213%50.2% | 0.9+83.8%21.7% | 0.5+568%201% | 0.1—50.3% | |
| Interest expense and finance costs | — | — | 2.3−85.4%17.8% | 16−0.0%132% | 16+9.1%139% | 14r14+41.0%153% | 10—178% | — | — | — | |
| Net interest income | — | — | — | — | −16—−139% | −14—−153% | −10—−178% | 0—0.0% | 0—0.0% | −0.0—−2.7% | |
| Other non-operating income (expense) | −15—−127% | −6.7−2968%−55.9% | 0.2—1.8% | −6.1—−51.7% | −15—−130% | −12—−125% | −7.7−1294%−137% | 0.6+64.7%15.5% | 0.4—160% | — | |
| Income before tax | −50—−428% | −61—−504% | −63—−491% | −78—−659% | −78—−700% | −84—−908% | −88—−1554% | −64—−1521% | −66—−26873% | −45—−30951% | |
| Income tax | −0.1−108%−0.6% | 0.9—7.0% | −0.1−271%−0.6% | 0.0+800%0.4% | 0.0—0.0% | −0.1−153%−1.2% | 0.2−57.2%3.7% | 0.5+84.6%11.8% | 0.3—109% | 0—0.0% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | −45—−30951% | |
| Net income attributable to shareholders | −50—−428% | −62—−511% | −62—−490% | −78—−659% | −78—−700% | −84—−907% | −88—−1558% | −64—−1533% | −66—−26981% | −45—−30951% | |
| Earnings per share, basic | -2.15—— | -4.94—— | -7.61r-0.76—— | -12.59r-1.26—— | -1.40—— | -1.55—— | -1.62—— | -1.18—— | -1.29—— | -1.01—— | |
| Earnings per share, diluted | -2.15—— | -4.94—— | -7.61r-0.76—— | -12.59r-1.26—— | -1.40—— | -1.55—— | -1.62—— | -1.18—— | -1.29—— | -1.01—— | |
| Shares, weighted average (basic) | 23+86.8%— | 12+51.9%— | 8.2r82+33.1%— | 6.2r62−89.0%— | 56+2.8%— | 55+0.0%— | 54+0.8%— | 54+5.5%— | 51+14.0%— | 45—— | |
| Shares, weighted average (diluted) | 23+86.8%— | 12+51.9%— | 8.2r82+33.1%— | 6.2r62−89.0%— | 56+2.8%— | 55—— | — | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 15+24.4%52.9% | 12−65.2%38.7% | 35−12.5%53.7% | 40+11.5%48.0% | 36−41.4%38.3% | 61−7.9%45.4% | 66+132%35.8% | 29+48.2%22.7% | 19−84.0%23.2% | 121—86.6% | |
| Short-term investments | 1.2+10.9%4.2% | 1.1−89.9%3.4% | 11—16.4% | — | — | — | — | — | — | — | |
| Receivables | 2.0−22.3%7.1% | 2.6+9.3%8.4% | 2.4r2.4+3.4%3.7% | 2.3+49.7%2.8% | 1.6−51.9%1.7% | 3.2+73.2%2.4% | 1.9−4.4%1.0% | 1.9+5624%1.6% | 0.0−55.8%0.0% | 0.1—0.1% | |
| Inventory | 2.9−13.8%10.0% | 3.3−36.3%10.6% | 5.2+2.5%8.0% | 5.1−45.0%6.1% | 9.2+14.4%9.9% | 8.1+4.0%6.0% | 7.7−3.9%4.2% | 8.1—6.4% | 0—0.0% | — | |
| Other current assets | 0.8−44.3%3.0% | 1.5−25.1%4.8% | 2.0+30.0%3.1% | 1.6−12.5%1.9% | 1.8+52.8%1.9% | 1.2+102%0.9% | 0.6+23.1%0.3% | 0.5+156%0.4% | 0.2+1425%0.2% | 0.0—0.0% | |
| Current assets | 22−9.1%77.9% | 24−56.3%78.0% | 56−23.6%86.2% | 73−10.6%88.3% | 82−32.7%87.8% | 122−31.4%90.6% | 178+47.4%95.9% | 120+53.6%96.0% | 78−41.5%94.7% | 134—96.3% | |
| Property, plant and equipment | 2.6+7.8%9.0% | 2.4−31.3%7.6% | 3.5−35.5%5.3% | 5.4−12.2%6.5% | 6.1−22.4%6.6% | 7.9+8.2%5.9% | 7.3+49.3%3.9% | 4.9+14.8%3.9% | 4.3−15.1%5.1% | 5.0—3.6% | |
| Right-of-use (leased) assets | 2.9+147%10.2% | 1.2−36.7%3.8% | 1.9−25.9%2.9% | 2.5−21.1%3.0% | 3.2−18.7%3.4% | 3.9—2.9% | — | — | — | — | |
| Other intangible assets | — | — | — | — | — | — | 0.1−14.9%0.1% | 0.1−8.2%0.1% | 0.1−7.0%0.2% | 0.2—0.1% | |
| Total assets | 29−9.0%100% | 31−51.8%100% | 65−21.7%100% | 83−11.1%100% | 93−30.5%100% | 134−27.4%100% | 185+47.6%100% | 126+51.5%100% | 83−40.5%100% | 139—100% | |
| Accounts payable | 4.8+1.0%17.0% | 4.8+6.6%15.3% | 4.5+127%6.9% | 2.0+53.7%2.4% | 1.3−45.1%1.4% | 2.4+77.8%1.7% | 1.3−36.4%0.7% | 2.1+110%1.7% | 1.0−62.2%1.2% | 2.6—1.9% | |
| Debt due within a year | — | 0.7−98.7%2.3% | 56+70416%86.8% | 0.1−85.5%0.1% | 0.6—0.6% | 0—0.0% | — | — | — | — | |
| Current liabilities | 31+159%109% | 12−81.9%38.4% | 67+858%102% | 6.9−0.3%8.4% | 7.0−14.6%7.5% | 8.2+5.1%6.1% | 7.8+14.4%4.2% | 6.8+68.2%5.4% | 4.0−23.9%4.9% | 5.3—3.8% | |
| Long-term debt | — | — | — | 0−100%0.0% | 4.7—5.0% | 0—0.0% | — | — | — | 0—0.0% | |
| Lease liabilities (non-current) | 2.6+351%9.0% | 0.6−63.1%1.8% | 1.5−35.1%2.4% | 2.4−22.3%2.9% | 3.1−14.4%3.3% | 3.6—2.7% | — | — | — | — | |
| Total liabilities | 85+65.1%296% | 51−41.3%163% | 87−26.1%134% | 118−24.4%142% | 156+10.2%167% | 142+10.9%105% | 128+1779%69.0% | 6.8+35.2%5.4% | 5.0−20.1%6.1% | 6.3—4.5% | |
| Retained earnings | −719—−2518% | −669—−2132% | −607—−934% | −571—−687% | −493—−528% | −415—−308% | −330—−178% | −242—−193% | −177—−214% | −111—−79.6% | |
| Shareholders' equity | −56—−196% | −20—−63.4% | −22—−34.2% | −35—−42.2% | −63r−63—−67.3% | −7.4−113%−5.5% | 57−51.7%31.0% | 119+52.5%94.6% | 78−41.5%93.9% | 133—95.5% | |
| Total liabilities and equity | 29−9.0%100% | 31−51.8%100% | 65−21.7%100% | 83−11.1%100% | 93−30.5%100% | 134−27.4%100% | 185+47.6%100% | 126+51.5%100% | 83−40.5%100% | 139—100% | |
| Shares outstanding | 25+72.9%— | 15+49.5%— | 9.7r97−85.6%— | 68+17.4%— | 58+5.3%— | 55+0.9%— | 54r54−2.6%— | 56+8.1%— | 52+0.6%— | 51r51—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.4+7.7%12.0% | 1.3−23.5%10.8% | 1.7−15.0%13.3% | 2.0−16.7%17.0% | 2.4+4.3%21.5% | 2.3−8.0%24.7% | 2.5+13.6%44.1% | 2.2−4.3%52.7% | 2.3r2.3+27.8%935% | 1.8r1.8—1224% | |
| Share-based compensation | 4.4−18.7%37.5% | 5.4−49.3%44.7% | 11−51.8%83.3% | 22+33.9%187% | 16+30.5%147% | 13−12.5%136% | 14+3.5%254% | 14+58.8%334% | 8.8+4.6%3567% | 8.4—5706% | |
| Cash from operating activities | −24—−207% | −40—−333% | −49—−382% | −47—−402% | −50—−451% | −65—−697% | −68—−1195% | −56—−1335% | −53—−21711% | −35—−23895% | |
| Capital expenditure | −0.5—−4.4% | −1.0—−8.6% | −0.6—−4.3% | −0.6—−5.1% | −1.4—−12.2% | −0.3—−3.5% | −1.0—−17.6% | −3.0—−71.0% | −2.4—−979% | −3.7—−2487% | |
| Cash from investing activities | −0.5−106%−4.4% | 8.7−30.3%71.8% | 12+49.5%97.4% | 8.3−39.0%70.5% | 14−74.2%122% | 53—568% | −20—−355% | −26—−616% | −50—−20150% | −2.7—−1820% | |
| Debt issued | 15—128% | 0—0.0% | 0—0.0% | 0−100%0.0% | 5.6—50.0% | 0—0.0% | — | — | — | — | |
| Debt repaid | −0.7—−6.2% | 0—0.0% | −0.1—−0.6% | −0.4—−3.1% | −0.4—−3.3% | 0—0.0% | 0—0.0% | — | — | — | |
| Shares issued | — | — | 33−23.3%258% | 43+11844%364% | 0.4−75.4%3.2% | 1.5—15.7% | — | — | — | — | |
| Shares bought back | — | — | — | — | 0—0.0% | 0—0.0% | −45—−795% | 0—0.0% | 0—0.0% | — | |
| Cash from financing activities | 27+200%231% | 9.0−71.5%74.8% | 32−26.8%248% | 43+272%367% | 12+70.5%104% | 6.8−94.6%73.4% | 126+39.1%2218% | 90+5032%2165% | 1.8−98.3%716% | 105—71308% | |
| Exchange-rate effect on cash | 0.6—5.2% | −0.3—−2.1% | −0.3—−2.4% | −0.1—−0.8% | −0.1—−0.7% | −0.1—−0.9% | −0.1−141%−2.3% | 0.3—7.6% | −0.1—−51.6% | 0—0.0% | |
| Change in cash | 3.0—25.3% | −23—−189% | −5.0−221%−39.2% | 4.1—34.9% | −25—−226% | −5.2−114%−56.4% | 38+307%666% | 9.3—222% | −101−251%−41196% | 67—45593% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Dec 31, 2024 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 | Q3 FY2022to Sep 30, 2022 | Q2 FY2022to Jun 30, 2022 | Q1 FY2022to Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 12−3.0%100% | 2.8*−7.0%100% | 3.0−9.8%100% | 3.0+2.2%100% | 2.9+3.9%100% | 3.0*+1.8%100% | 3.3+11.5%100% | 2.9−24.3%100% | 2.8−4.9%100% | 3.0—100% | 3.0—100% | 3.9—100% | 3.0—100% | |
| Cost of revenue | 9.0−5.4%76.9% | 2.4*−1.1%84.1% | 2.1−33.6%71.2% | 2.3+8.9%77.4% | 2.2+22.0%75.2% | 2.4*+12.3%79.1% | 3.2+34.1%96.8% | 2.1−23.7%72.6% | 1.8−16.5%64.0% | 2.1*—71.7% | 2.4r2.2—80.4% | 2.8—72.0% | 2.2—72.9% | |
| Gross profit | 2.7+6.0%23.1% | 0.4*−29.1%15.9% | 0.9+700%28.8% | 0.7−15.4%22.6% | 0.7−28.5%24.8% | 0.6*−24.8%20.9% | 0.1−81.5%3.2% | 0.8−26.0%27.4% | 1.0+26.1%36.0% | 0.8—28.3% | 0.6r0.8—19.6% | 1.1—28.0% | 0.8—27.1% | |
| Research and development | 17−34.2%143% | 3.8*−32.2%134% | 3.8−45.1%129% | 3.9−32.9%131% | 5.2−25.8%177% | 5.6*−7.6%184% | 7.0−4.0%212% | 5.8−23.2%199% | 7.0+15.7%248% | 6.0*—203% | 7.3—246% | 7.6—196% | 6.0—204% | |
| Selling, general and administrative | 21−31.7%182% | 4.6*−20.5%164% | 5.6−27.4%189% | 5.4−28.9%180% | 5.7−43.5%195% | 5.8*−34.0%191% | 7.8−6.0%235% | 7.6−34.2%259% | 10−5.3%359% | 8.8*—295% | 8.3—279% | 11—298% | 11—361% | |
| Total costs and expenses | 38−32.8%325% | 8.4*−26.2%298% | 9.5−35.8%318% | 9.3−30.6%311% | 11−36.3%372% | 11*−23.2%375% | 15−5.0%447% | 13−29.8%458% | 17+2.3%607% | 15*—498% | 16—525% | 19—494% | 17—564% | |
| Operating income | −35—−302% | −7.9*—−282% | −8.6—−290% | −8.6—−288% | −10—−348% | −11*—−354% | −15—−444% | −13—−431% | −16—−571% | −14—−470% | −15r−15—−505% | −18—−466% | −16—−537% | |
| Interest and finance income | 0.7−37.4%6.0% | 0.2*+3.0%7.4% | 0.2−27.2%6.0% | 0.1−54.5%3.9% | 0.2−52.4%6.8% | 0.2*−49.5%6.7% | 0.2+237%7.5% | 0.3+355%8.7% | 0.4+1809%14.9% | 0.4*—13.5% | 0.1—2.5% | 0.1—1.5% | 0.0—0.7% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | — | — | — | — | 0.7—18.5% | 0.9—31.0% | |
| Other non-operating income (expense) | −15—−127% | −1.7*—−61.2% | −6.0−138%−202% | −3.0—−99.9% | −4.1—−139% | −1.7*—−56.3% | 16—476% | −20—−684% | −0.7−130%−26.1% | −0.7*—−24.4% | −0.9—−31.6% | −0.5r0.2—−13.8% | 2.4r1.7—82.2% | |
| Income before tax | −50—−428% | −9.7*—−343% | −15−1506%−492% | −12—−388% | −14—−487% | −12*—−411% | 1.0—31.6% | −33—−1115% | −17—−597% | −15*—−494% | −16r−16—−537% | −19r−18—−480% | −13r−14—−455% | |
| Income tax | −0.1−108%−0.6% | −0.1*−112%−2.3% | 0−100%0.0% | 0−100%0.0% | 0—0.0% | 0.6*—18.6% | 0.1—4.0% | 0.2—5.3% | 0—0.0% | −0.1*—−2.6% | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −50—−428% | −9.6*—−341% | −15−1709%−492% | −12—−388% | −14—−487% | −13*—−429% | 0.9—27.6% | −33—−1121% | −17—−597% | −15—−491% | −16r−16—−537% | −19r−18—−480% | −13r−14—−455% | |
| Earnings per share, basic | — | — | -0.59−1083%— | -0.50—— | -0.74—— | — | 0.06—— | -2.97—— | -1.71r-0.17—— | -0.14—— | -1.83r-0.18—— | -2.43r-0.23—— | -0.20r-0.21—— | |
| Earnings per share, diluted | — | — | — | -0.50—— | -0.74—— | — | 0.06—— | -2.97—— | -1.71r-0.17—— | -0.14—— | -1.83r-0.18—— | -2.43r-0.23—— | -0.20r-0.21—— | |
| Shares, weighted average (basic) | — | — | 25+72.6%— | 23+109%— | 19+95.5%— | — | 14+65.9%— | 11+44.4%— | 9.8r98−85.5%— | — | 8.7r87—— | 7.6r76—— | 68—— | |
| Shares, weighted average (diluted) | — | — | — | 23+109%— | 19+95.5%— | — | 15+67.3%— | 11+44.4%— | 9.8r98−85.5%— | — | 8.7r87—— | 7.6r76—— | 68—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 15—52.9% | 15+24.4%52.9% | 20−2.3%60.9% | 8.6−70.7%37.6% | 15−50.3%47.5% | 12−65.2%38.7% | 20−48.3%51.3% | 29+539%58.7% | 29+115%57.7% | 35—53.7% | 39—51.4% | 4.6—7.8% | 14—19.4% | |
| Short-term investments | 1.2—4.2% | 1.2+10.9%4.2% | 1.2+23.5%3.8% | 1.2—5.1% | 1.1—3.7% | 1.1−89.9%3.4% | 1.0—2.5% | — | — | 11—16.4% | — | — | — | |
| Receivables | 2.0—7.1% | 2.0−22.3%7.1% | 2.0−24.0%6.3% | 2.3−2.3%10.0% | 2.2−8.7%7.2% | 2.6+9.3%8.4% | 2.7+11.4%6.8% | 2.3−20.2%4.7% | 2.4+14.8%4.8% | 2.4r2.4—3.7% | 2.4—3.2% | 2.9—5.0% | 2.1—3.0% | |
| Inventory | 2.9—10.0% | 2.9−13.8%10.0% | 3.0−16.2%9.2% | 3.2−36.9%14.1% | 3.2−38.3%10.6% | 3.3−36.3%10.6% | 3.6−34.1%9.0% | 5.1−3.7%10.2% | 5.3−4.3%10.3% | 5.2—8.0% | 5.4—7.1% | 5.3—9.0% | 5.5—7.8% | |
| Other current assets | 0.8—3.0% | 0.8−44.3%3.0% | 1.0−72.8%3.1% | 1.1−60.4%4.9% | 1.8+17.3%6.0% | 1.5−25.1%4.8% | 3.6+84.3%9.3% | 2.8+73.7%5.6% | 1.6−1.2%3.1% | 2.0—3.1% | 2.0—2.6% | 1.6—2.8% | 1.6—2.3% | |
| Current assets | 22—77.9% | 22−9.1%77.9% | 27−15.4%84.9% | 17−59.4%75.1% | 24−43.7%78.6% | 24−56.3%78.0% | 32−51.0%82.5% | 42−12.1%84.7% | 43−29.9%84.0% | 56—86.2% | 66—87.4% | 48—81.8% | 61—86.9% | |
| Property, plant and equipment | 2.6—9.0% | 2.6+7.8%9.0% | 2.9+10.3%8.9% | 3.1+7.0%13.6% | 3.2−0.6%10.4% | 2.4−31.3%7.6% | 2.6−27.9%6.6% | 2.9−29.3%5.8% | 3.2−37.0%6.3% | 3.5—5.3% | 3.6—4.8% | 4.1—7.0% | 5.1—7.3% | |
| Right-of-use (leased) assets | 2.9—10.2% | 2.9+147%10.2% | 0.6−54.7%1.9% | 0.8−48.5%3.4% | 1.0−43.6%3.1% | 1.2−36.7%3.8% | 1.4−32.8%3.4% | 1.5−30.0%3.1% | 1.7−27.7%3.3% | 1.9—2.9% | 2.0—2.7% | 2.2—3.7% | 2.3—3.3% | |
| Total assets | 29—100% | 29−9.0%100% | 32−17.8%100% | 23−54.2%100% | 31−39.8%100% | 31−51.8%100% | 39−48.2%100% | 50−15.1%100% | 51−27.5%100% | 65—100% | 76—100% | 59—100% | 70—100% | |
| Accounts payable | 4.8—17.0% | 4.8+1.0%17.0% | 4.7−2.0%14.6% | 3.8−6.8%16.4% | 5.1+44.9%16.6% | 4.8+6.6%15.3% | 4.8+70.7%12.2% | 4.0+81.6%8.1% | 3.5+29.7%6.9% | 4.5—6.9% | 2.8—3.7% | 2.2—3.8% | 2.7—3.9% | |
| Debt due within a year | — | — | 0−100%0.0% | 0−100%0.0% | 0.7−98.7%2.4% | 0.7−98.7%2.3% | 0.7+807%1.8% | 0.7+764%1.5% | 57+68918%111% | 56—86.8% | 0.1—0.1% | 0.1—0.1% | 0.1—0.1% | |
| Current liabilities | 31—109% | 31+159%109% | 18−51.7%56.5% | 13−75.0%58.7% | 16−76.3%52.5% | 12−81.9%38.4% | 38−42.8%96.1% | 54−19.7%108% | 68−40.2%134% | 67—102% | 66r9.6—87.1% | 67r11—114% | 114r8.2—162% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | |
| Lease liabilities (non-current) | 2.6—9.0% | 2.6+351%9.0% | 0−100%0.0% | 0.1−92.2%0.4% | 0.3−74.9%1.1% | 0.6−63.1%1.8% | 0.8−54.0%2.1% | 1.1−46.7%2.1% | 1.3−40.3%2.6% | 1.5—2.4% | 1.8—2.3% | 2.0—3.4% | 2.2—3.1% | |
| Total liabilities | 85—296% | 85+65.1%296% | 81+8.7%250% | 58−34.8%253% | 57−37.0%184% | 51−41.3%163% | 74−13.4%189% | 89−26.6%178% | 90−29.0%176% | 87—134% | 86r86—113% | 121—206% | 126r127—180% | |
| Retained earnings | −719—−2518% | −719—−2518% | −709—−2195% | −695—−3038% | −683—−2223% | −669—−2132% | −656—−1668% | −657—−1317% | −624—−1224% | −607—−934% | −593r−592—−781% | −577—−982% | −558r−559—−793% | |
| Shareholders' equity | −56—−196% | −56—−196% | −48—−150% | −35—−153% | −26—−83.9% | −20—−63.4% | −35—−89.1% | −39—−77.5% | −39—−75.9% | −22—−34.2% | −10.0r−9.8—−13.2% | −62r−62—−106% | −56r−57—−79.7% | |
| Total liabilities and equity | 29—100% | 29−9.0%100% | 32−17.8%100% | 23−54.2%100% | 31−39.8%100% | 31−51.8%100% | 39−48.2%100% | 50−15.1%100% | 51−27.5%100% | 65—100% | 76—100% | 59—100% | 70—100% | |
| Shares outstanding | 25—— | 25+72.9%— | 25+71.6%— | 24+64.9%— | 22−78.1%— | 15+49.5%— | 15−85.1%— | 14−82.0%— | 100+45.0%— | 9.7r97—— | 97—— | 80—— | 69—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.4+7.6%12.0% | 0.4*+35.4%13.3% | 0.3+8.9%11.5% | 0.4−0.8%11.8% | 0.3−6.8%11.3% | 0.3*−33.4%9.2% | 0.3−17.3%9.5% | 0.4−20.1%12.1% | 0.4−22.8%12.6% | 0.4*—14.0% | 0.4—12.9% | 0.4—11.5% | 0.5r0.5—15.6% | |
| Share-based compensation | 4.4−18.7%37.5% | 1.0*−29.3%34.2% | 1.2−36.4%38.8% | 1.0−41.6%32.4% | 1.3+134%44.4% | 1.4*−44.2%45.1% | 1.8+47.7%55.0% | 1.7−58.4%56.6% | 0.6−81.4%19.7% | 2.4*—82.3% | 1.2—41.5% | 4.0—103% | 3.0—101% | |
| Cash from operating activities | −24—−207% | −5.1*—−180% | −3.1*—−104% | −7.6*—−254% | −8.5—−289% | −7.8*—−256% | −8.3*—−250% | −11*—−370% | −13—−475% | −9.6*—−321% | −14*—−459% | −13*—−337% | −13—−426% | |
| Capital expenditure | — | 0*—0.0% | — | −0.0*—−0.1% | −0.5—−17.6% | −0.1*—−3.6% | −0.8*—−23.0% | −0.2*—−5.3% | −0.0—−0.4% | −0.1*—−3.6% | — | 0*—0.0% | −0.4—−15.1% | |
| Cash from investing activities | −0.5−106%−4.4% | 0*—0.0% | 0.0*—0.2% | −0.0*−100%−0.1% | −0.5−106%−17.6% | −0.1*−102%−3.6% | −0.4*−102%−10.7% | 0.9*−79.3%31.3% | 8.2—292% | 5.8*—197% | 16*—533% | 4.4*—115% | −14—−461% | |
| Debt repaid | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | 0*—0.0% | — | — | −0.1*—−2.5% | — | — | — | |
| Shares issued | — | — | — | — | — | — | — | — | — | 0*—0.0% | 33*—1111% | 0*—0.0% | 0—0.0% | |
| Cash from financing activities | 27+200%231% | −0.6*−648%−20.8% | 15*—498% | 1.4*−85.8%46.8% | 11—392% | 0.1*—3.5% | −0.8*−103%−24.8% | 9.8*—336% | −0.1−200%−2.7% | −0.1*—−4.2% | 32*—1082% | −0.4*—−9.2% | 0.1—2.6% | |
| Exchange-rate effect on cash | 0.6—5.2% | 1.1*—37.7% | −0.6*−303%−20.7% | 0.2*—5.7% | −0.0—−0.2% | −0.3*—−8.8% | 0.3*+96.1%9.2% | −0.0*—−0.9% | −0.3—−9.3% | −0.2*—−8.3% | 0.2*—5.2% | −0.1*—−3.8% | −0.1—−2.5% | |
| Change in cash | 3.0—25.3% | −4.6*—−163% | 11*—373% | −6.0*—−202% | 2.5—84.5% | −8.0*—−265% | −9.1*−127%−276% | −0.1*—−4.3% | −5.5—−195% | −4.1*—−137% | 34*—1162% | −9.1*—−235% | −26—−887% | |
| Report | Worked out | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Accelerate Diagnostics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Bankruptcy or receivershipFiling
- Delisting noticeFiling
- Bankruptcy or receivershipDebt called earlyFiling
- Delisting noticeFiling
- Auditor changedFiling
- Delisting noticeFiling
And 1 more in the list below.
Bankruptcy or receivership 2 · Delisting notice 4 · Auditor changed 1 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 6 · New debt 2 · Unregistered share sale 2 · Shareholder vote 1 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Bankruptcy or receivershipAcquisition or sale completedMaterial agreement | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Delisting notice | 8-K | |
| Bankruptcy or receivershipDebt called earlyMaterial agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Auditor changed | 8-K | |
| Directors and officers | 8-K | |
| Unregistered share sale | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K/A | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 18, 2025
Acquisitions and funding#
6 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2022 | $4 M | No. 6 | $2 to $10 million | 3 | equity | SEC |
| Sep 2021 | $30 M | No. 5 | $10 to $50 million | 3 | equity | SEC |
| Dec 2020 | $2 M | No. 4 | Under $2 million | 5 | equity | SEC |
| May 2014 | $20 M | No. 3 | $10 to $50 million | 4 | equity | SEC |
| Aug 2013 | $3 M | No. 2 | $2 to $10 million | 1 | equity | SEC |
| Jun 2012 | $14 M | No. 1 | $10 to $50 million | 1 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Accelerate Diagnostics, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $65 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Data ScientistStatisticians | 1 | $65 K |
Where: Tucson, AZ 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $65 K | 1 |
| FY2022 | 1 | 1 | $65 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Accelerate Diagnostics, Inc.
Product recalls by Accelerate Diagnostics, Inc.#
3 recalls since 2015, 376 units in the notices that give a number. Medical devices (FDA): 3.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Accelerate PhenoTest BC kit REF 10101018 (and 1 more products)Due improperly formulated and released bulk lot of fluorescence in situ hybridization (FISH) probes resulting in false positive identification results for Staphylococcus aureus and Streptococcus spp.Medical devicesClass II | 200 | Z-0345-2023 | |
| Accelerate PhenoTest BC kit, Ref #10101018. The firm name on the label is Accelerate Diagnostics, Tucson, AZ. A multiplexed in-vitro diagnostic test intended for use with the Accelerate Pheno system.The kits may produce an elevated rate of false positive calls for the Staphylococcus aureus identification probe (SAU).Medical devicesClass II | 95 | Z-1529-2018 | |
| Accelerate Pheno system, with Accelerate Pheno System Software 1.2.1 - 1.3.1, PSW000012B Product Usage: The Accelerate Pheno system is intended to measure signal intensity of fluorescent probes bound to nucleic acid in target and non-target organisms and to take time-lapse dark-field images of immobilized growing bacterial cell…Rare isolates of Enterobacteriaceae may generate a susceptible meropenem Minimum Inhibitory Concentration (MIC) using the affected device and a resistant result by broth microdilution. In order to mitigate any risk associated with these rare isolates, the firm has implemented an Expert Rule that suppresses the meropenem result for isolates that display a profile consistent with those that generated a false-susceptible result. The firm has responded to this risk by implementing a set of suppression rules, in a software update, to prevent incorrect results.Medical devicesClass II | 81 | Z-1065-2019 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Accelerate Diagnostics, Inc. compares in Diagnostics and Research
- Revenue$12 M · higher than 16% of 123
- Net margin-427.7% · higher than 3% of 112
- Revenue growth-3.0% · higher than 23% of 89
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Accelerate Diagnostics, Inc.🇺🇸 | $58 M | — | -427.7% | -3.0% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Thermo Fisher Scientific Inc.$253.8 B
- Danaher Corporation$166.7 B
- WuXi AppTec Co., Ltd.$70.4 B
- Natera, Inc.$58.7 B
- Siemens Healthineers AG$52.8 B
- Lonza Group AG$51.9 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Employees:
- 2019
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, Wikidata, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Accelerate Diagnostics, Inc.? Verify and update this profile — free
Show Accelerate Diagnostics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.